A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

• ClinicalTrials.gov Identifier: NCT02797964
• Recruitment Status: Completed
• First Posted: June 14, 2016
• Results First Posted: March 10, 2022
• Last Update Posted: March 10, 2022
• Sponsor: Sierra Oncology, Inc.
• Information provided by (Responsible Party): Sierra Oncology, Inc.

Study Description

Brief Summary:

The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in prospectively-selected subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to checkpoint kinase 1 (Chk1) inhibition via synthetic lethality. Specific cancer indications that frequently harbor these genetic mutations will be studied.

Condition or disease	Intervention/treatment	Phase
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)	Drug: SRA737	Phase 1; Phase 2

Detailed Description:

SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of cell cycle progression and the DNA Damage Response (DDR) replication stress response. In cancer cells, intrinsic replication stress (RS) is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in DNA repair machinery (e.g. BRCA1 or FANCA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or RAD50) or other genomic alterations. This replication stress results in persistent DNA damage and genomic instability, leading to an increased dependency on Chk1 for survival. Targeted inhibition of Chk1 by SRA737 may therefore be synthetically lethal to cancer cells with elevated intrinsic RS.

This study has been designed to: establish the safety profile; determine the pharmacokinetic profile; identify the optimal dose, schedule, and MTD; obtain preliminary evidence of activity; and evaluate SRA737's efficacy in prospectively-selected subjects with tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition via synthetic lethality.

This clinical study consists of two phases, a Dose Escalation Phase 1 portion and a Cohort Expansion Phase 2 portion.

In the Dose Escalation Phase 1 portion, cohorts consisting initially of a single subject will receive escalating doses of SRA737, administered orally on a continuous daily dosing schedule in 28-day cycles. Once an SRA737-related Grade 2 toxicity is observed in a dose escalation cohort during Cycle 1, that cohort will be expanded to 3 to 6 subjects, and subsequent dose level cohorts will follow a rolling 6 design until the MTD has been identified.

In the Cohort Expansion Phase 2 portion, subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition will be prospectively enrolled into six indication-specific cohorts to explore the preliminary efficacy of SRA737. Subjects must have advanced or metastatic disease of one of the following types:

• castration-resistant prostate cancer (mCRPC);
• high grade serous ovarian cancer (HGSOC) without CCNE1 gene amplification;
• HGSOC with CCNE1 gene amplification (or alternative genetic alteration with similar functional effect);
• non-small cell lung cancer (NSCLC);
• head and neck squamous cell carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA); and
• colorectal cancer (mCRC).

To qualify for enrolment in the Cohort Expansion Phase 2 portion, the subject's tumor must have a confirmed combination of mutations which are expected to confer sensitivity to Chk1 inhibition, determined by the Sponsor's review of genetic abnormalities detected in the following categories:

• Oncogenic drivers such as CCNE1 or MYC, etc.
• Genes involved in the DNA repair process including BRCA1, BRCA2, FANC genes, mismatch repair (MMR) genetic alterations and/or high microsatellite instability.
• Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as TP53, RAD50, etc. For patients with HNSCC or SCCA, positive human papilloma virus (HPV) status is also considered for eligibility.
• Genetic indicators of replicative stress such as gain of function/amplification of CHEK1, ATR or other related genes.

Tumor genetics will be prospectively determined using Next-Generation Sequencing.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 107 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
• Actual Study Start Date: July 2016
• Actual Primary Completion Date: October 28, 2019
• Actual Study Completion Date: October 28, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Open label	Drug: SRA737; SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With Adverse Events as Assessed by CTCAE 4.03 [ Time Frame: Up to 30 days after last dose of SRA737 ]
   Treatment-emergent adverse events (TEAEs) were reported until the safety Follow up (SFU) visit, 30 days after the last dose of SRA737 or prior to the initiation of a new anticancer treatment, whichever came first.
2. Maximum Tolerated Dose of SRA737 [ Time Frame: Cycle 1 (28 days) in the Dose Escalation Phase ]
   The highest dose at which ≤ 33% of subjects have a dose limiting toxicity (DLT) in a cohort of up to 6 subjects.
3. Recommended Phase 2 Dose of SRA737 [ Time Frame: Up to 30 days after last dose of SRA737 ]
   The RP2D and schedule were defined by the Cohort Review Committee at the end of the study and took all clinically relevant toxicity, PK and PDn data into account. The RP2D was to be a dose equal to or less than the MTD for the selected schedule.
4. Disease Control Rate (DCR) of SRA737 [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. ]
   The disease control rate (DCR) was defined as the number of subjects achieving complete response (CR) + partial response (PR) + stable disease (SD) per RECIST 1.1 criteria. Since no subjects achieved CR or PR in this study, the DCR represents the proportion of subjects in each group who achieved SD.
5. Time to Progression (TTP) [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]
   Time to progression (TTP) was defined as the time from Cycle 1 Day 1 to the earliest date of radiographic disease progression per RECIST 1.1, or if the subject did not experience disease progression, to the last imaging assessment. TTP was analyzed using the K-M method.
6. Progression Free Survival (PFS) [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]
   Progression free survival (PFS) was defined as time from Cycle 1 Day 1 to the earliest date of radiographic disease progression per RECIST 1.1 or death, whichever happened first. Censoring rules are defined in the SAP. PFS was analyzed using the K-M method.
7. Overall Survival (OS) [ Time Frame: Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]
   Overall survival (OS) was defined as time from Cycle 1 Day 1 to the date of death (or date last known to be alive). OS was analyzed using the K-M method.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

1. For Dose Escalation Only: any locally advanced or metastatic, histologically or cytologically proven solid tumor or NHL, relapsed after or progressing despite conventional treatment
2. Life expectancy of at least 12 weeks
3. World Health Organization (WHO) performance status of 0-1
4. Must meet select hematological and biochemical laboratory indices
5. Archival tumor tissue or accessible tumor and willingness to consent to a biopsy

Expansion Only:

1. Any locally advanced or metastatic malignancy of the following types for which no other conventional therapy is considered appropriate:

   • Metastatic Colorectal Cancer (CRC)
   • Platinum-resistant or intolerant High Grade Serious Ovarian Cancer (HGSOC)
   • Advanced Non-Small Cell Lung Cancer (NSCLC)
   • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
   • Head and Neck Squamous Cell Carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA).
   • Eligibility may be further restricted by the select number of prior regimens specific to each indication

2. Measurable disease per RECIST v1.1, or for mCRPC, evaluable disease per any of the following:

   • Measurable disease per RECIST v1.1
   • Increasing PSA
   • Circulating tumor cell (CTC) count of 5 or more cells per 7.5 ml of blood

3. Tumor tissue or ctDNA evidence that subject's tumor harbors a combination of mutations which are expected to confer sensitivity to Chk1 inhibition. Eligibility will be determined by the Sponsor's review of genetic abnormalities detected in genes in the following categories:

   • Oncogenic drivers such as MYC, CCNE1, etc.
   • Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RAD50, TP53, etc. For patients with NHSCC or SCCA, positive HPV status is also considered for eligibility.
   • The DDR pathway including BRCA1, BRCA2 and FANC. For patients with CRC, MMR genetic alterations and/or high microsatellite instability are also considered for eligibility.
   • Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.

Key Exclusion Criteria:

1. Received the following prior or current anticancer therapy:

   • Radiotherapy within the last 6 weeks
   • Endocrine therapy during the previous 4 weeks
   • Chemotherapy during the previous 4 weeks
   • Immunotherapy during the previous 6 weeks
   • Nitrosoureas or Mitomycin C during the previous 6 weeks
   • Other Investigational Medicinal Product during the 4 weeks before treatment
   • Any prior treatment with a Chk1 inhibitor or prior treatment with an ATR inhibitor within 6 months prior to receiving SRA737
2. Other malignancy within the past 2 years, except for adequately treated tumors
3. Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1
4. For Dose Escalation: new or progressing brain metastases. For Cohort Expansion: present or prior brain metastases
5. High medical risk because of nonmalignant systemic disease
6. Serologically positive for hepatitis B, hepatitis C or HIV
7. Serious cardiac condition, left ventricular ejection fraction < 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment
8. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within 8 weeks
9. Peanut allergy
10. QTcF> 450 msec in adult males and > 470 msec in adult females
11. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737
12. Inability to swallow capsules without chewing or crushing
13. Is a participant or plans to participate in another interventional clinical trial
14. Any other condition which in the Investigator's opinion would not make the subject a good candidate

Contacts and Locations

Locations

United Kingdom

Royal Marsden Hospital

Sutton, London, United Kingdom, SM2 5PT

Belfast City Hospital

Belfast, Northern Ireland, United Kingdom, BT9 7AB

Oxford University Hospitals

Headington, Oxford, United Kingdom, OX3 7LE

Velindre Cancer Centre - Cardiff

Cardiff, Whitchurch, United Kingdom, CF14 2TL

The Clatterbridge Cancer Centre

Bebington, Wirral, United Kingdom, CH63 4JY

Western General Hospital

Edinburgh, United Kingdom, EH4 2XU

The Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom, G12 0YN

The Leeds Teaching Hospitals of St James University Hospital

Leeds, United Kingdom, LS9 7TF

University Hospitals of Leicester

Leicester, United Kingdom, LE1 5WW

Guy's and St. Thomas

London, United Kingdom, SE1 9RT

Sarah Cannon Research Institute

London, United Kingdom, W1G 6AD

University College London Hospitals

London, United Kingdom, W1T 7HA

The Christie

Manchester, United Kingdom, M20 4BX

Freeman Hospital

Newcastle upon Tyne, United Kingdom, NE7 7DN

Sheffield Teaching Hospitals

Sheffield, United Kingdom, S10 2SJ

Sponsors and Collaborators

Sierra Oncology, Inc.

  Study Documents (Full-Text)

Documents provided by Sierra Oncology, Inc.:

Study Protocol  [PDF] January 10, 2018

Statistical Analysis Plan: Revised (final) statistical analyses  [PDF] January 22, 2021

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jin T, Xu L, Wang P, Hu X, Zhang R, Wu Z, Du W, Kan W, Li K, Wang C, Zhou Y, Li J, Liu T. Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile. J Med Chem. 2021 Oct 28;64(20):15069-15090. doi: 10.1021/acs.jmedchem.1c00994. Epub 2021 Oct 19.

• Responsible Party: Sierra Oncology, Inc.
• ClinicalTrials.gov Identifier: NCT02797964
• Other Study ID Numbers: SRA737-01
• First Posted: June 14, 2016
• Results First Posted: March 10, 2022
• Last Update Posted: March 10, 2022
• Last Verified: March 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Sierra Oncology, Inc.:

Replication stress; Advanced solid tumors; CCNE1; TP53; BRCA1; BRCA2; MYC; RAD50; Fanconi anemia; Cell cycle; Metastatic Colorectal Cancer; Platinum-Resistant or Intolerant High Grade Serious Ovarian Cancer; Advanced Non-Small Cell Lung Cancer; Metastatic Castration-Resistant Prostate Cancer; Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Anus; Phase 1; Phase 2; Dose escalation; Chk1 inhibitor; Checkpoint kinase 1; Synthetic lethality; Next-Generation Sequencing; Genetic biomarkers

Additional relevant MeSH terms:

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases